Basilea Raises 2026 Profit Outlook on Cresemba Sales Growth

3-line summary

• Swiss pharmaceutical company Basilea raised its 2026 profit outlook, citing sales growth of its antifungal drug Cresemba, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.